Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC

Non-small Cell Lung Cancer Clinical Trial

Official title:

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01772732
• Other study ID #: SIM-101-1
• Status: Recruiting
• Phase: Phase 1
• First received: January 15, 2013
• Last updated: April 7, 2015
• Start date: December 2012
• Est. completion date: December 2015

Study information

• Verified date: April 2015
• Source: Jiangsu Simcere Pharmaceutical Co., Ltd.
• Contact: Yuankai Shi, MD
• Phone: 86-10-87788268
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective is to assess the safety and tolerability of multiple doses of Simotinib Hydrochloride in NSCLC patients. The secondary objective is to determine the pharmacokinetic (PK) profile and explore the preliminary anti-tumor activity.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Patients with histologically or cytologically confirmed diagnosis of advanced NSCLC, who were previously treated with at least one platinum-based chemotherapy regimen, but had disease relapse;

• Patients have ended their chemotherapy or radiotherapy at least 4 weeks prior to study entry and have recovered from any previous toxicity;

• EGFR mutation positive (such as E19del?L858R?L861Q?G719X, etc.);

• Patients with at least one measurable lesion meeting RECIST;

• ECOG performance status 0-2;

• Life expectancy =12 weeks;

• Adequate bone marrow function: ANC =1.5 × 109/L, PLT=80 ×109/L, HB =90 g/L;

• Adequate hepatic function: serum bilirubin = 2 × ULN, AST and ALT = 2.5 × ULN, and = 5 × ULN are acceptable if the liver has tumor involvement;

• Adequate renal function: endogenous creatinine clearance rate (CrCl) = 60 mL/min or serum creatinine = 1.5 × ULN;

• Females with childbearing potential must have a negative pregnancy test within 7 days prior to treatment and use an approved contraceptive method during the study;

• Males must be surgically sterile or use an approved contraceptive method during the study.

Exclusion Criteria:

• Patients who were previously treated by EGFR inhibitor or other molecular targeting drugs (micromolecular drugs or monoclonal antibodies) such as Iressa, Tarceva, Sutent, Nexavar, Sprycel, Erbitux, Nimotuzumab, Icotinib, Herceptin, etc.;

• The known hypersensitivity to Simotinib or any of the excipients;

• Concurrent treatment with rifampin, rifabutin, rifapentine, dexamethasone, phenytoin sodium, carbamazepine, phenobarbital, Hypericum perforatum, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin;

• CNS metastasis diagnosed recently which has not received surgery or radiotherapy;

• Evidence of interstitial lung disease;

• Pre-existing idiopathic pulmonary fibrosis as evidenced by CT scan at baseline;

• Any serious or uncontrollable systemic disease (such as unstable respiratory disorders, cardiovascular, hepatic or kidney disorders);

• Any unstable systemic disorders (including active infection, uncontrollable hypertension, unstable angina pectoris, congestive heart failure, liver and kidney disorders or metabolism disease);

• Other malignancies diagnosed within the last 5 years with the exception of completely cured cervical cancer in situ, or basal and squamous cell skin cancer;

• Any remarkable eye disorders, especially severe dry eye syndrome, keratoconjunctivitis sicca, herpes keratitis;

• History of nerve or psychiatric disorders, including epilepsy or dementia.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Simotinib Hydrochloride

Locations

Country	Name	City	State
China	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Jiangsu Simcere Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose (MTD)		28 days	Yes
Secondary	The maximum plasma concentration (Cmax)		d1,d8,d9,d10,d15	No
Secondary	The time to Cmax (tmax)		d1,d8,d9,d10,d15	No
Secondary	Area under the plasma concentration-time curve (AUC)		d1,d8,d9,d10,d15	No
Secondary	Overall Response Rate (ORR)		1 year	No
Secondary	Progression-free Survival (PFS)		1 year	No